

COMPANY FACT SHEET



Antigenics is working to develop treatments for cancers and infectious diseases. The company's investigational product portfolio includes Oncophage® (vitespen; formerly HSPPC-96), a patient-specific therapeutic cancer vaccine being evaluated in more than nine different cancer

indications; Aroplatin™, a liposomal, third-generation platinum chemotherapeutic; AG-707, a therapeutic vaccine for the treatment of genital herpes; and QS-21, a vaccine adjuvant being evaluated by Antigenics' corporate licensees in several late-stage clinical trials.

LEADERSHIP

Executive Management

Garo H. Armen, PhD
Chairman and Chief Executive Officer

John Cerio
Vice President, Human Resources

Deanna M. Petersen
Vice President, Business Development

Shalini Sharp
Chief Financial Officer and Vice President

Sunny Uberoi
Vice President, Corporate Communications

Karen Higgins Valentine
Vice President, Legal

Kerry A. Wentworth
Vice President, Clinical Operations and Regulatory Affairs

Directors

Garo H. Armen, PhD
Chairman and Chief Executive Officer

Brian Corvese
Vencor Capital

Tom Dechaene

Margaret M. Eisen, CFA

John N. Hatsopoulos
American DG Energy

Wadih Jordan
NearEast Pharma

Hyam I. Levitsky, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Peter Thornton
Elan Corporation

Timothy R. Wright
Tyco Healthcare

CORPORATE HIGHLIGHTS

PHASE 3 DATA FOR ONCOPHAGE IN NONMETASTATIC RENAL CELL CARCINOMA SHOW 45-PERCENT IMPROVEMENT IN RECURRENCE-FREE SURVIVAL IN INTERMEDIATE-RISK PATIENTS

IN PHASE 3 TRIAL OF ONCOPHAGE IN METASTATIC MELANOMA, OVERALL MEDIAN SURVIVAL WAS 29 PERCENT LONGER IN PATIENTS WHO RECEIVED AT LEAST 10 INJECTIONS OF ONCOPHAGE

PHASE 2, INVESTIGATOR-SPONSORED TRIAL OF ONCOPHAGE IN GLIOMA ONGOING AT UCSF; PRELIMINARY DATA SHOW IMMUNE RESPONSE IN ALL TREATED PATIENTS

PHASE 1 CLINICAL TRIAL OF NEW AROPLATIN FORMULATION IN SOLID TUMORS AND B-CELL LYMPHOMA ONGOING; DATA EXPECTED TO BE ANNOUNCED IN 2008

PHASE 1 STUDY OF AG-707 IN GENITAL HERPES ONGOING; DATA EXPECTED TO BE ANNOUNCED IN 2008

QS-21 STIMULON® ADJUVANT BEING EVALUATED BY ANTIGENICS' CORPORATE LICENSEES IN MORE THAN 20 VACCINE INDICATIONS, INCLUDING SEVERAL IN LATE-STAGE CLINICAL TRIALS

INTELLECTUAL PROPERTY POSITION SECURE WITH TECHNOLOGIES PROTECTED BY MORE THAN 80 ISSUED US PATENTS

Members of the Medical Advisory Council

EXECUTIVE COMMITTEE

Michael Atkins, MD
Beth Israel Deaconess Medical Center

Ronald M. Bukowski, MD
Cleveland Clinic

Hyam I. Levitsky, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Andrew T. Parsa, MD, PhD
University of California, San Francisco


Mace L. Rothenberg, MD
Vanderbilt-Ingram Cancer Center

MEMBERS

John M. Kirkwood, MD
The University of Pittsburgh Cancer Institute

Larry W. Kwak, MD, PhD
M. D. Anderson Cancer Center

Giorgio Parmiani, MD
Istituto Nazionale per lo Studio e la Cura dei Tumori



NASDAQ: AGEN

SHARES OUTSTANDING
45,889,301

MARKET CAPITALIZATION
\$134.0 MILLION (6/20/07)

INVESTOR RELATIONS
ROBERT ANSTEY
TEL: 800.962.AGEN (2436)
E-MAIL: IR@ANTIGENICS.COM

CORPORATE COMMUNICATIONS
SUNNY UBEROI
TEL: 212.994.8206
E-MAIL: SUBEROI@ANTIGENICS.COM

CORPORATE HEADQUARTERS
162 FIFTH AVENUE, SUITE 900
NEW YORK, NY 10010
TEL: 212.994.8200
FAX: 212.994.8299

RESEARCH, DEVELOPMENT
AND MANUFACTURING
3 FORBES ROAD
LEXINGTON, MA 02421
TEL: 781.674.4400
FAX: 781.674.4200

ANTIGENICS.COM

PRODUCT HIGHLIGHTS

Oncophage®

Oncophage is an investigational, patient-specific therapeutic cancer vaccine based on gp96, a heat shock protein (HSP). It is designed to capture the 'antigenic fingerprint' of the individual patient's specific cancer to stimulate the immune system to recognize unique antigens present only on cancer cells.

Data from Antigenics' Phase 3 trial of Oncophage in nonmetastatic renal cell carcinoma (RCC, the most common type of kidney cancer) showed a 44-percent improvement in recurrence-free survival associated with Oncophage in a well-defined subgroup of intermediate-risk (better-prognosis) patients. In a Phase 3 study of Oncophage in metastatic melanoma, overall median survival was 29 percent longer in patients who received at least 10 injections of Oncophage compared with physician's choice regimen. Preliminary findings from an investigator-sponsored, Phase 1/2 study evaluating Oncophage as a treatment for recurrent glioma, being conducted at the University of California, San Francisco, showed tumor-specific immune response in all treated patients, which may be associated with clinical benefit in this patient population. Antigenics also plans to investigate Oncophage in clinical trials of combination treatment.

Potentially applicable to all cancer types, Oncophage has been studied in more than 750 patients in more than nine cancer indications to date and has been found to be well tolerated. The HSP technology has been independently validated by more than 25 laboratories worldwide and documented in more than 150 publications.

Oncophage has received fast track and orphan drug designations from the US Food and Drug Administration (FDA) for both renal cell carcinoma and melanoma, as well as orphan drug designation for renal cell carcinoma in Europe.

Aroplatin™ (liposomal platinum chemotherapeutic)

Aroplatin is an investigational liposomal formulation of a novel, proprietary platinum chemotherapeutic. It is a third-generation compound (similar to Eloxatin® [oxaliplatin], Sanofi-Aventis, an approved treatment for colorectal cancer) that is designed to enhance bioavailability, have fewer side effects, and have applicability to a broader range of cancers than current platinum drugs. Antigenics has developed an improved formulation of Aroplatin intended to enhance its pharmacologic activity. The reformulation is currently being evaluated in a Phase 1 clinical trial involving patients with advanced solid tumors and B-cell lymphoma.

AG-707

AG-707 is an investigational therapeutic vaccine for the treatment of genital herpes, representing Antigenics' first non-patient-specific application of its HSP technology. Based on AG-702, an earlier vaccine that contained a single antigen from the genital herpes virus (herpes simplex virus 2, or HSV-2), AG-707 is a polyvalent (multiple-antigen) therapeutic vaccine that is designed to treat HSV-2 infection in a broad population of patients. AG-707 is currently being evaluated in a multicenter Phase 1 clinical trial.

QS-21 Stimulon® adjuvant

One of the most widely tested vaccine adjuvants under development, Antigenics' QS-21 Stimulon adjuvant is being licensed by industry leaders such as GlaxoSmithKline, Elan, Acambis, Progenics and Advanced Bioscience Laboratories. Currently being evaluated in more than 20 indications, it is a critical component in the development of preventative vaccine formulations across a wide variety of infectious diseases as well as multiple new-generation therapeutic vaccines to treat cancer and degenerative disorders. The first vaccine containing QS-21 could reach the market as early as 2009.

RESEARCH & DEVELOPMENT

Antigenics' founding technology platform is based on heat shock proteins, a ubiquitous class of proteins involved in generating immune response. HSP technology is being applied in both patient-specific and off-the-shelf treatment settings. In addition, Antigenics is assessing the use of HSP-based therapies in combination with other treatments as well as developing a higher-activity Oncophage.

PRODUCT PIPELINE

		Phase 1/2	Phase 2	Phase 3
CANCER				
Oncophage	Renal cell carcinoma (nonmetastatic)			●
	Melanoma			●
	Renal cell carcinoma (metastatic)		●	
	Non-small cell lung cancer	●		
	Glioma**	●		
	Solid tumors and B-cell lymphoma*	●		
Aroplatin	Colorectal cancer		●	
	Solid tumors	●		
INFECTIOUS DISEASE				
AG-707	Genital herpes*		●	
PARTNERED PROGRAMS				
QS-21 Stimulon® adjuvant	More than 20 indications	●	●	●

*Currently enrolling
 †Investigator-sponsored